Traws Pharma, Inc. (NASDAQ:TRAW) Sees Large Increase in Short Interest

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 141,900 shares, an increase of 1,956.5% from the December 31st total of 6,900 shares. Approximately 5.2% of the shares of the company are sold short. Based on an average trading volume of 503,100 shares, the short-interest ratio is presently 0.3 days.

Traws Pharma Price Performance

Shares of Traws Pharma stock remained flat at $7.38 during trading on Wednesday. 85,046 shares of the stock were exchanged, compared to its average volume of 153,010. The stock’s fifty day simple moving average is $6.73. Traws Pharma has a fifty-two week low of $4.06 and a fifty-two week high of $27.50. The stock has a market cap of $26.94 million, a P/E ratio of -0.05 and a beta of 1.13.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.